alexa Design And Evaluation Of A Novel OspA-based Vaccine For The Prevention Of Lyme Borreliosis | 20520
ISSN: 2157-7560

Journal of Vaccines & Vaccination
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

4th International Conference on Vaccines & Vaccination

Andreas Meinke
ScientificTracks Abstracts: J Vaccines Vaccin
DOI: 10.4172/2157-7560.S1.020
Abstract
A t present, there is no vaccine available to prevent Lyme borreliosis in humans, although it has been shown that the disease can be averted by immunization with an OspA based vaccine (LYMErix?). In Europe three Borrelia species, B. afzelii , B. burgdorferi and B. garinii are the main pathogens causing Lyme borreliosis, the most common tick-borne zoonosis. Outer surface protein A (OspA) is one of the dominant antigens expressed by the spirochetes when present in the tick vector. The various pathogenic Borrelia species express different OspA serotypes on their surface: B. burgdorferi (serotype 1), B. afzelii (serotype 2), B. garinii (serotypes, 3, 5 and 6) and B. bavariensis (serotype 4). In order to target these Borrelia species, we have designed a multivalent OspA-based vaccine. The vaccine includes three proteins, each containing the C-terminal half of two OspA serotypes linked to form a heterodimer. In order to stabilize the C-terminal fragment and thus preserve important structural epitopes, disulfide bonds were introduced and the immunogenicity increased by addition of a lipidation signal. Active immunization with the adjuvanted Lyme borreliosis vaccine protected mice from a challenge with spirochetes expressing either OspA serotype 1, 2 or 5, using infected ticks or in vitro grown bacteria as a challenge. Further immunological analyses (ELISA, surface binding and growth inhibition) indicated that the vaccine can provide protection against the majority of human pathogenic Borrelia species. This rational designed OspA-based vaccine is therefore suitable for global prophylaxis of Lyme borreliosis
Biography
Andreas Meinke obtained his PhD in 1992 from the University of Freiburg and the University of British Columbia in Vancouver, Canada. Subsequent to his work at UBC, he moved to the Department of Microbiology and Genetics, University Vienna, as an Assistant Professor. In 1998, he joined the newly founded biotech company Intercell AG, now Valneva Austria GmbH. At present he is responsible at Valneva for pre-clinical and translational research. He has authored and co-authored more than 60 publications, lectured in several university programs and filed more than 20 patents in the field of antigen discovery and vaccine development
image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7